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Abstract 
The goal to eliminate malaria from the Asia‑Pacific by 2030 will require the safe and widespread delivery of effec‑
tive radical cure of malaria. In October 2017, the Asia Pacific Malaria Elimination Network Vivax Working Group met 
to discuss the impediments to primaquine (PQ) radical cure, how these can be overcome and the methodological 
difficulties in assessing clinical effectiveness of radical cure. The salient discussions of this meeting which involved 110 
representatives from 18 partner countries and 21 institutional partner organizations are reported. Context specific 
strategies to improve adherence are needed to increase understanding and awareness of PQ within affected commu‑
nities; these must include education and health promotion programs. Lessons learned from other disease programs 
highlight that a package of approaches has the greatest potential to change patient and prescriber habits, however 
optimizing the components of this approach and quantifying their effectiveness is challenging. In a trial setting, the 
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Background
In November 2014 the governments of the Asia-Pacific 
nations reconfirmed their commitment to the regional 
malaria elimination by 2030 [1]. Over the last decade 
major gains in malaria control have been made, but these 
successes have been far less apparent for Plasmodium 
vivax than for Plasmodium falciparum. One of the great-
est challenges in achieving the ambitious goal of malaria 
elimination is widespread implementation of the effective 
radical cure of malaria, in which all stages of the parasite 
are targeted. The propensity of P. vivax to form dormant 
liver stages (hypnozoites) and to recur, requires the pro-
vision of treatment of both the blood and liver stages of 
the parasite [2]. Currently, the only widely available drug 
to eliminate hypnozoites from the human host is pri-
maquine (PQ). The World Health Organization (WHO) 
treatment guidelines recommend that PQ is adminis-
tered over 14 days to reduce the risk of severe haemolysis 
[3]. Tafenoquine (TQ), another investigational 8-amino-
quinoline compound currently under review by US Food 
and Drug Administration and the Australian Therapeutic 
Goods Administration, has a significantly longer half-life 
than PQ and, therefore, can be administered as a single 
dose regimen. However, the prolonged drug concen-
trations raise concerns over its potential to cause sus-
tained haemolysis in G6PD intermediate and deficient 
individuals, highlighting the need for appropriate G6PD 
screening.
When supervised, a 14-day regimen of PQ can reduce 
the risk of recurrent P. vivax infection by more than 85% 
[4, 5]. However in most clinical scenarios daily supervi-
sion of a prolonged treatment regimen is not feasible. 
When drug administration is not supervised the clinical 
effectiveness of a 14-day course of PQ can be compro-
mised severely [5–9]. In a recent large-scale observa-
tional study of 68,000 patients with vivax malaria in 
Papua, Indonesia, the effectiveness of unsupervised PQ 
was estimated to be at best 12% [10]. Whilst adherence 
to a 14  days regimen can be mitigated by reducing the 
duration of treatment [11], even an unsupervised 7 days 
regimen has been shown to be suboptimal [12]. Radical 
cure with a single dose of TQ will overcome many of the 
issues of adherence, however the challenges of ensuring 
concomitant G6PD testing will ensure that in many loca-
tions PQ regimens will still be the only available treat-
ment option. Thus there is an urgent need to understand 
the determinants of adherence and to develop innova-
tive approaches to improve anti-malarial effectiveness in 
malaria endemic areas. Investigation, rationalization and 
validation of novel interventions to improve adherence, 
requires measuring clinical effectiveness and this also 
poses specific challenges above and beyond conventional 
efficacy clinical trials.
As part of the ongoing collaborative efforts towards 
the elimination of malaria in the Asia-Pacific region, the 
annual meeting of the Vivax Working Group (VxWG) of 
the Asia-Pacific Malaria Elimination Network (APMEN) 
[13] was convened in Bali, Indonesia, in October 2017. 
The meeting was attended by 110 representatives from 
18 partner countries and 21 institutional partner organi-
zations. Data were presented on the challenges of adher-
ence to antimalarial treatment regimens, lessons from 
the management of other infectious diseases, and clini-
cal trials methodology. In addition two round table dis-
cussions were held to discuss (i) whether adherence to 
PQ radical cure was an issue, and if so how this could be 
overcome and (ii) methodological challenges in assessing 
anti-malarial efficacy and effectiveness of P. vivax infec-
tion. The specific questions posed to the groups are listed 
in Tables 1 and 2. The key discussion points are summa-
rized into 4 categories: (i) impediments to PQ adherence 
at the level of the patient and health system, and suitable 
strategies to overcome these, (ii) tools and strategies that 
can be used from other disease programmes to improve 
adherence, (iii) measuring the effectiveness of PQ radical 
cure, and (iv) increasing the understanding of effective-
ness and adherence using mixed methods research.
Topic 1: Impediments to PQ adherence at the level 
of the patient and health system, and suitable 
strategies to overcome these
Vivax malaria is often perceived as a benign disease and 
there is a lack of understanding and awareness regard-
ing the benefits of radical cure; this constitutes the main 
impediment for PQ adherence at the patient level. There 
reactivity of participants results in patients altering their behaviour and creates inherent bias. Although bias can be 
reduced by integrating data collection into the routine health care and surveillance systems, this comes at a cost of 
decreasing the detection of clinical outcomes. Measuring adherence and the factors that relate to it, also requires an 
in‑depth understanding of the context and the underlying sociocultural logic that supports it. Reaching the elimina‑
tion goal will require innovative approaches to improve radical cure for vivax malaria, as well as the methods to evalu‑
ate its effectiveness.
Keywords: Vivax malaria, Plasmodium vivax, Adherence, Effectiveness, Efficacy, Radical cure, Primaquine, APMEN
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is a disconnect with the treatment of an acute febrile ill-
ness and the subsequent high risk of recurrent episodes 
of malaria, which are often regarded as new infections. 
Adherence to medication is influenced by a combination 
of social representation of medicines, such as the cultural 
and social meanings attributed to drugs and the cultural 
constructions of certain brand names [14, 15].
The beliefs among healthcare workers and policy mak-
ers were also regarded as being crucial, and these result 
in low rates of prescription, even when PQ is part of local 
and national treatment guidelines [16]. The perceived 
lack of benefit of radical cure is compounded in some 
locations by concerns regarding the potential side-effects 
of PQ, particularly the risk of haemolysis. Concerns 
regarding haemolysis and PQ toxicity, were apparent 
particularly in areas where G6PD deficiency could not 
be diagnosed reliably [16]. The lack of clear protocols to 
monitor and report haemolytic events after PQ treat-
ment were mentioned as additional concerns. The acute 
febrile illness of vivax malaria is treated with standard 
schizontocidal drugs, but the additional prescription of 
PQ for the prevention of future recurrent infections is 
often regarded as being of secondary importance. Hence, 
concerns regarding potential adverse effects and the lack 
of immediate benefits, influence prescribing habits.
The need for better staff training and increased aware-
ness about the individual and community benefits of 
radical cure were identified as a key strategy to overcome 
poor adherence by both the patient and the health pro-
vider. Participants highlighted the need for context spe-
cific strategies to improve adherence, including education 
and health promotion programmes aimed at increasing 
understanding and awareness within affected communi-
ties. Other interventions perceived as potentially ben-
eficial included more intensive patient monitoring, which 
could be integrated with other disease programmes or 
home visits. This would reassure clinicians that if adverse 
events occurred they would be identified and managed 
promptly. Incentives could be devised to encourage pro-
viders to prescribe PQ and intermittent reminders could 
be provided to patients through mobile phone technolo-
gies to prompt them to continue treatment after their 
symptoms had abated.
Additional points raised during the discussion, 
included involving the private health sector in adherence 
monitoring, improved access to quality drugs, robust 
supply chains and the need for paediatric PQ formula-
tions. Packaging aids such as blister packs or prepackag-
ing compared to bulk package as well as pictorial inserts 
as suggested previously [17] were also deemed to be 
potential strategies (Table 3).
Topic 2: Tools and strategies used in other disease 
programs that can improve PQ adherence
Experiences from other disease programmes highlight 
the importance of adopting multiple approaches to 
improving adherence to treatment. A combination of 
efforts is needed and this should involve a multidisci-
plinary team of healthcare professionals (social work-
ers, doctors, nurses, and counselors), patients (including 
close family members and carers) and the community 
(religious centres, community health organizations/
agents and activists) [18]. Patient education and coun-
seling were considered to be critical for all approaches, 
since  both have been shown to improve patient-health-
care provider relationship, and provision of individual-
ized and patient-centered care [19].
Education and counseling can be achieved at an indi-
vidual level or at a family/group level. These approaches 
should include education about clinical consequences of 
vivax malaria, its propensity to recur and its treatment. 
Simple and pictorial stories and pamphlets can be used to 
increase patients’ competencies and knowledge. Health 
Table 1 Questions posed to participants for the first round table discussion
What are the main impediments of adherence from a patient perspective?
What are the main impediments of adherence from health care system perspective?
How can adherence be improved on the patient level?
How can adherence be improved on a health care system level?
Can methods from other disease programs be applied to malaria?
How can adherence to radical cure guidelines be improved?
How and what methods to increase adherence can be integration into current infrastructure?
What research is needed to better inform programs to improve adherence?
Table 2 Questions posed to  participants for  the  second 
round table discussion
Quantifying effectiveness: what outcome measures are needed?
Quantifying effectiveness: how can observer biasbe minimized?
How can adherence be assessed in study setting/real life?
What should be priorities in qualitative surveys around adherence?
What public health interventions are needed to increase effectiveness of 
PQ?
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talks to the general public attending the hospital or health 
centre to disseminate information about malaria and 
suitable preventive treatments were considered feasible. 
The provision of easy and low cost adherence aids can 
help patients remember their medications and the order 
and timing at which they should be taken. For instance, 
a pill box, in which doses are divided up by days or a pill 
taking table, can be filled in by the patient or someone 
supporting their treatment; these remind patients to take 
their medication, which tablets have already been taken 
and which tablets are still remaining. Alternative options 
include setting alarm clocks or mobile phone alarms to 
remind patients when to take the medication or match-
ing pill taking to the patient’s daily activities (e.g. before, 
or after a meal, or prior to a daily activity) [20]. Treat-
ment support outside the health centre can be provided 
by either family members or community health agents. 
In Nepal a patient-responsive approach including both 
of these strategies has been shown to improve the adher-
ence to tuberculosis treatment [21].
An integrated package of interventions was generally 
perceived to be more useful than single intervention. 
Furthermore the most suitable interventions are likely to 
be context specific. Thorough evaluation of the efficacy 
and effectiveness of new approaches including cost–
benefit analyses is needed for National Malaria Control 
Programmes (NMCPs) to make informed decisions on 
optimal strategies.
Topic 3: Quantifying PQ effectiveness to optimize 
suitable interventions
Most anti-malarial clinical trials measure treatment effi-
cacy, which refers to the ability of a regimen to achieve 
cure in an ideal scenario. Effectiveness is the extent to 
which a drug regimen achieves its intended effect in the 
real world setting. To determine effectiveness one needs 
to document the clinical outcome, such as recurrent epi-
sodes of malaria or associated anaemia, but in such a way 
as to minimize the influence on patient and prescriber 
behavior. Two questions were posed to participants: how 
can adherence be measured reliably and how reactiv-
ity can be minimized without compromising the trial’s 
integrity?
Typical measures of adherence include self-reporting, 
pill count and biological assays. Self-reporting is used 
widely since it is relatively easy and cheap to implement, 
however it is also subjective, highly dependent on how 
questions are asked, prone to recall and social desirabil-
ity bias [22]. Using text messaging as a self-reporting tool 
was discussed as a potential way to reduce social desir-
ability bias. Computer administration has been shown to 
increase reporting levels of sensitive questions compared 
to interviewer-based administration of questionnaires 
[22–24]. However interactive text-messaging relies on 
significant infrastructure and few studies have estimated 
its reliability [22].
Pill counts are also simple to implement using either 
manual counting or an electronic pill cap [25, 26]. Man-
ual pill counts are usually undertaken during follow up 
visits at the health facility, with patients asked to bring 
the empty pill box or empty blister packs. However, this 
method is also prone to potential bias, since patients are 
aware that their compliance is being assessed. Home vis-
its or unannounced calls to patients were discussed as a 
more appropriate to estimate true adherence, although 
this raises ethical considerations requiring prior consent 
when enrolled into the study [27, 28]. Electronic pill caps, 
were considered the reference standard of indirect adher-
ence measures. These record the opening of the pill box, 
the underlying assumption being that bottle opening rep-
resents medication intake, however this level of complex-
ity comes at a greater financial cost [29].
Biological assays offer another measure of adherence. 
Plasma drug concentrations can be quantified to demon-
strate that drug doses were ingested, however these are 
confounded by the actual dose prescribed, its timing with 
respect to sampling, gastrointestinal absorption, metab-
olism and elimination. Furthermore such approaches 
require invasive sampling from either capillary or venous 
blood samples, and involve significant infrastructure 
Table 3 Solutions to improve adherence to PQ
Main problem Suitable interventions
Low patients adherence to PQ Increase awareness among the general patient population about the benefits or radical cure through education and 
health promotion programs (health talks) and individual patients counseling
Increased patient monitoring integrated into other disease programs, through home visits, incentives, pill boxes or 
automated reminders via text messages
Packaging aids including pictorial inserts
Better PQ formulations for children
Low provider adherence to PQ Better staff training to increase awareness among staff about the benefits or radical cure and how to discuss these 
with patients
Involvement of private sector in adherence monitoring. Improved access to quality drugs
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to ensure adequate sample storage and analysis. PQ is 
metabolized rapidly with a half-life of less than 6  h, so 
may be undetected within 24  h of administration [30]. 
Its metabolite, carboxy-PQ, is more slowly eliminated 
and accumulates over the course of a 14 day course and 
may therefore be a more useful measure of adherence 
[30]. Correlation of carboxy-PQ plasma concentrations 
and adherence requires knowledge of the normal phar-
macokinetic profile of the drug when administered under 
supervision in a variety of populations; however this has 
yet to be defined. Sparse sampling similar to population 
pharmacokinetic studies with a probability score as out-
come measure was discussed as a potential solution, but 
such approaches need to be validated in carefully con-
trolled settings.
Quantifying methaemoglobin (Met-Hb) concentrations 
is another potential proxy measure of adherence. Met-Hb 
concentrations are elevated following PQ administration 
since the drug induces oxidative stress on red blood cells 
resulting in oxidization of the ferrous iron in the haem 
group [31]. Met-Hb can be measured non-invasively 
using a finger probe to measure arterial oxygen-Hb satu-
ration. Similar to the interpretation of blood drug con-
centrations, the normal variation of Met-Hb following 
supervised PQ therapy needs to be defined. Furthermore 
Met-Hb concentration may be elevated due to other rea-
sons besides PQ administration and thus validation of 
this approach is needed. A study in Bangladesh showed 
no clear correlation between Met-Hb levels and pill 
counts [32] and recent data from Brazil also indicated 
no correlation between the plasma PQ concentrations or 
total dose and Met-Hb levels [33], although further clini-
cal studies are underway to explore this further.
Anti-malarial clinical efficacy trials require patient 
observation to capture the relevant study outcomes. 
However the act of observing people alters their behav-
iour, a phenomenon often described as reactivity or 
observation bias in psychological research and behav-
ioural science [34–36]. Patients enrolled into a study 
often do not behave as they would in real life, just 
because they are aware that they are in a study, are being 
observed and receiving a therapeutic intervention. Com-
parative efficacy trials can mitigate this potential bias 
by “blinding” treatment so that either the patient and/
or the clinician are unaware of the treatment arm they 
are receiving. Although this reduces behavioural bias 
between treatment arms being compared, it does not 
overcome changes in behaviour inherent in being under 
scrutiny. Hence adherence in intervention and con-
trol groups often do not reflect reality. Reactivity can 
be reduced by minimising observation or by using less 
obtrusive measures, such as unannounced pill counts as 
discussed previously [28]. Early enrolment and consent of 
a cohort before malaria infection and treatment occurs, 
using a cluster design was suggested as a way to reduce 
reactivity as the effect can be expected to wane over time 
[36]. Studies that are integrated into the routine health 
care systems rather than stand-alone trials provide an 
alternative way of capturing clinical outcomes under nor-
mal clinical practice, although these are confounded by a 
lack of a control arm, residual confounding and attrition 
bias [10].
Topic 4: Increasing our understanding 
of effectiveness and adherence using mixed 
methods research
Reducing reactivity alone is insufficient to ensure robust 
measures of effectiveness or the effect of novel interven-
tions targeting adherence. Measuring adherence and the 
factors that relate to it requires an in-depth understand-
ing of the context and the underlying sociocultural logic 
that underlie it [37]. This requires a better understanding 
of the implicit heterogeneity in behaviour, cultural diver-
sity and variability in social structural conditions under-
lying adherence.
Qualitative methods provide an important approach 
that can inform the optimal design of quantitative adher-
ence studies. Contextual information can facilitate the 
selection processes to minimize bias, determine specific 
sub-groups at risk of being excluded, inform the opera-
tionalization of concepts to be measured, and aid the 
interpretation of the results. Suitable qualitative methods 
such as ethnography constitute effective tools to provide 
an in-depth understanding of the factors contributing to 
adherence. These data should be central to the design of 
appropriate intervention strategies to impact on behav-
iour and clinical outcomes. Quantitative measures of 
adherence need to consider the sociocultural specificities 
and thus are likely to vary considerably between different 
endemic settings. It is unlikely that a single approach can 
be proposed for suitable interventions or the design of an 
effectiveness trial that is widely applicable across a wide 
range of environments. However further exploration 
may reveal certain common elements that can be applied 
universally.
Various additional constraints for the delivery of effec-
tive radical cure were mentioned and considered to 
require a more in-depth and locally relevant understand-
ing. These included human mobility and how this affects 
adherence and follow up, and patients’ flexible health 
seeking itineraries and therapeutic choices, such as the 
private, traditional sectors and home treatment.
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Conclusions
In the light of the 2030 elimination goal, the delivery of 
effective radical cure for malaria is a high priority for the 
vivax endemic areas of the Asia-Pacific Region, Horn of 
Africa and South and Meso-Americas. The design and 
evaluation of appropriate interventions to improve effec-
tiveness of PQ treatment, as well as lessons learned from 
other disease programmes must be taken into account 
and the methodological challenges addressed.
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